Managing lung cancer with comorbid interstitial pneumonia

Research output: Contribution to journalReview article

Abstract

Systemic therapy for advanced non-small cell lung cancer (NSCLC) has dramatically changed in the latest 15 years. Molecular-targeted therapy has brought about an era of precision medicine, and immune checkpoint inhibitors have brought hope for a cure for advanced NSCLC. In the wake of this remarkable advancement, lung cancer with comorbid interstitial pneumonia (IP) has been completely left behind, as most clinical trials exclude patients with comorbid IP. IP, especially idiopathic pulmonary fibrosis (IPF), is often accompanied by lung cancer, and acute exacerbation can develop during various cancer therapies, including surgery, radiotherapy and pharmacotherapy. In this review, we focus on the clinical questions concerning pharmacotherapy in cases of advanced lung cancer with comorbid IP and discuss what we can do with the currently available data.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalInternal Medicine
Volume59
Issue number2
DOIs
Publication statusPublished - Jan 15 2020

Keywords

  • Interstitial pneumonia
  • Lung cancer

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Managing lung cancer with comorbid interstitial pneumonia'. Together they form a unique fingerprint.

  • Cite this